Discovery and development of the anticancer agent gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase
作者： Andy Barker , David Andrews
DOI: 10.1016/B978-0-12-397176-0.00008-X
关键词:
摘要: Abstract The epidermal growth factor receptor (EGFR) tyrosine kinase is a target for cancer chemotherapy. This chapter describes the discovery of small-molecule inhibitors kinase, their characterization and medicinal chemistry programme that resulted in identification gefitinib. development studies undertaken to progress drug clinic are presented together with brief summary other EGFR properties.
sci-hub.se 参考文章(24)
Philip Cohen, The role of protein phosphorylation in human health and disease. FEBS Journal. ,vol. 268, pp. 5001- 5010 ,(2001) , 10.1046/J.0014-2956.2001.02473.X
Koichi Goto, Yukito Ichinose, Yuichiro Ohe, Nobuyuki Yamamoto, Shunichi Negoro, Kazuto Nishio, Yohji Itoh, Haiyi Jiang, Emma Duffield, Rose McCormack, Nagahiro Saijo, Tony Mok, Masahiro Fukuoka, Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 7, pp. 115- 121 ,(2012) , 10.1097/JTO.0B013E3182307F98
Mark Sanford, Lesley J. Scott, Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs. ,vol. 69, pp. 2303- 2328 ,(2009) , 10.2165/10489100-000000000-00000
Joan Albanell, Pere Gascon, Small molecules with EGFR-TK inhibitor activity. Current Drug Targets. ,vol. 6, pp. 259- 274 ,(2005) , 10.2174/1389450053765888
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Axel Ullrich, Joseph Schlessinger, Signal transduction by receptors with tyrosine kinase activity Cell. ,vol. 61, pp. 203- 212 ,(1990) , 10.1016/0092-8674(90)90801-K
Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, Yi-Long Wu, James Chih-Hsin Yang, Da-Tong Chu, Meilin Liao, Yuh-Min Chen, Han-Pin Kuo, Shunichi Negoro, Kwok Chi Lam, Alison Armour, Patrick Magill, Masahiro Fukuoka, Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology. ,vol. 6, pp. 1872- 1880 ,(2011) , 10.1097/JTO.0B013E31822ADAF7
Jeffrey Jie-Lou Liao, Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors Journal of Medicinal Chemistry. ,vol. 50, pp. 409- 424 ,(2007) , 10.1021/JM0608107
Wenjun Zhou, Dalia Ercan, Pasi A. Jänne, Nathanael S. Gray, Discovery of selective irreversible inhibitors for EGFR-T790M Bioorganic & Medicinal Chemistry Letters. ,vol. 21, pp. 638- 643 ,(2011) , 10.1016/J.BMCL.2010.12.036
Andrew J Barker, Keith H Gibson, Walter Grundy, Andrew A Godfrey, Jeffrey J Barlow, Mark P Healy, James R Woodburn, Susan E Ashton, Brenda J Curry, Lynn Scarlett, Lianne Henthorn, Laura Richards, Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic & Medicinal Chemistry Letters. ,vol. 11, pp. 1911- 1914 ,(2001) , 10.1016/S0960-894X(01)00344-4